Provided by Tiger Trade Technology Pte. Ltd.

Meiragtx Holdings Plc

14.34
-0.2000-1.38%
Pre-market: 14.460.1170+0.82%04:03 EDT
Volume:635.48K
Turnover:9.12M
Market Cap:1.38B
PE:16.48
High:14.85
Open:14.70
Low:14.10
Close:14.54
52wk High:15.35
52wk Low:6.62
Shares:96.04M
Float Shares:53.68M
Volume Ratio:0.73
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8700
EPS(LYR):-1.4199
ROE:72.17%
ROA:38.65%
PB:6.39
PE(LYR):-10.10

Loading ...

MeiraGTx Holdings Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Apr 02

MeiraGTx price target lowered to $18 from $20 at Evercore ISI

TIPRANKS
·
Apr 01

MeiraGTx’s AI Push Raises Operational, Regulatory and Data Privacy Risk Concerns

TIPRANKS
·
Mar 31

MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.
·
Mar 31

MeiraGTx Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 27

MeiraGTx price target lowered to $26 from $30 at Piper Sandler

TIPRANKS
·
Mar 27

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Meiragtx Holdings (MGTX), Hims & Hers Health (HIMS) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
Mar 27

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

Reuters
·
Mar 27

MeiraGTx Holdings Plc : Piper Sandler Cuts Target Price to $26 From $30

THOMSON REUTERS
·
Mar 27

MeiraGTx Holdings (MGTX) Q3 Loss Of US$50.5m Reinforces Bearish Community Narratives

Simply Wall St.
·
Mar 27

MeiraGTx Hldgs Q4 EPS $0.19 Beats $(0.61) Estimate, Sales $75.364M Beat $3.869M Estimate

Benzinga Earnings
·
Mar 26

Gene therapy firm MeiraGTx's 2025 net loss narrows

Reuters
·
Mar 26

MeiraGTx FY2025 license revenue rises to $75 million; net loss per share narrows to $1.42

Reuters
·
Mar 26

BRIEF-MeiraGTx FY EPS USD -1.42

Reuters
·
Mar 26

MeiraGTx FY Income From Operations USD -105.968 Million

THOMSON REUTERS
·
Mar 26

Corrected-MeiraGTx FY Revenue USD 81.4 Million VS. Ibes Estimate USD 26 Million (Corrects Amount)

THOMSON REUTERS
·
Mar 26

Press Release: MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

Dow Jones
·
Mar 26

U.S. Earnings Preview: Before Market Open March 26

Dow Jones
·
Mar 26

MeiraGTx CEO Alexandria Forbes disposes of USD 459,420 in common shares

Reuters
·
Mar 25

U.S. Earnings Preview: Before Market Open March 19

Dow Jones
·
Mar 19